Table 1 Characteristics of studied group.
From: Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers
Numbers of patients (n = 117) | |
|---|---|
Age, median (range), years | 55 (16–80) |
<40 | 14 (11.97%) |
40–49 | 26 (22.22%) |
50–59 | 43 (36.75%) |
>=60 | 34 (29.06%) |
Site of Disease | |
Ovary (include primary peritoneal and fallopian tube) | 68 (58.12%) |
Cervix | 32 (27.35%) |
Endometrial | 17 (14.53%) |
Stage of Disease | |
stage I | 21 (17.95%) |
stage II | 34 (29.06%) |
stage III | 43 (36.75%) |
stage IV | 15 (12.82%) |
NA | 4 (3.42%) |
HPV status (Cervix cancer) | |
positive | 9 (28.13%) |
negative | 5 (15.63%) |
uncertain | 18 (56.25%) |
Subtype of Endometrial Carcinoma | |
Type I | 16 (94.12%) |
Type II | 1 (5.88%) |
Tissue types (in each cancer types) | |
Ovarian cancer | |
Serous adenocarcinoma | 59 (86.76%) |
Clear cell adenocarcinoma | 3 (4.41%) |
Endometroid adenocarcinoma | 1 (1.47%) |
Other | 5 (7.35%) |
Cervical cancer | |
Squamous cell carcinoma | 31 (96.88%) |
Mucinous adenocarcinoma | 1 (3.12%) |
Endometrial cancer | |
Endometroid adenocarcinoma | 16 (94.12%) |
Serous adenocarcinoma | 1 (5.88%) |
